# 听觉扭曲

[◀返回](./home.html)

**听觉扭曲**（Auditory distortion）就是体验到听到的声音在呈现和结构上发生了改变哦。

这些失真可以表现为多种风格，但通常采取回声或杂音的形式，随着每个声音的尾声升起，并伴随着速度和音调的波动变化呢。这种情况可能会加剧，直到声音持续伴随着不断的混响，通常会让原来的声音完全无法辨认。但是嘛，如果噪声源停止或改变，它通常会很快重置到基础水平并重新开始。

这种效应的体验可以分解为三个不同的强度等级。下面是对它们的描述和记录哦：

1.  **轻微** - 在最低的强度水平下，听觉扭曲包括外部环境中噪音的微妙和自发的混响、回声效应以及音调变化。它们是短暂的、强度低的，很容易被忽略呢。
2.  **明显** - 在这个水平上，听觉扭曲包括明显的、自发的的回声效应和归因于外部环境中噪音的音调变化。它们很长，拖得很慢，而且响亮到难以忽视哦。
3.  **完全包围** - 在最高水平上，听觉扭曲变得持续且无法忽视。由此产生的改变的复杂性很快就会让原来的声音变得难以理解。

听觉扭曲通常伴随着其他同时发生的效应，比如[听觉幻觉](/FreeODwiki/药效/听觉幻觉.html)、[听觉敏锐度抑制](/FreeODwiki/药效/听觉敏锐度抑制.html)和[听觉敏锐度增强](/FreeODwiki/药效/听觉敏锐度增强.html)。它们最常在[迷幻剂](/FreeODwiki/文档/药物分类/迷幻剂.html)类化合物（如[LSD](/FreeODwiki/药物/LSD.html)、[5-MeO-DiPT](/FreeODwiki/药物/5-MeO-DiPT.html)和[DMT](/FreeODwiki/药物/DMT.html)）的[中等](/FreeODwiki/文档/药物剂量分类.html#中等)[剂量](/FreeODwiki/文档/药物剂量分类.html)影响下被诱发。不过呢，它们也可能较少见地在[解离剂](/FreeODwiki/文档/药物分类/解离剂.html)（如[氯胺酮](/FreeODwiki/药物/氯胺酮.html)、[PCP](/FreeODwiki/药物/PCP.html)和[氧化亚氮](/FreeODwiki/药物/氧化亚氮.html)）的影响下发生。

#### 例子

[Both.ogg](/FreeODwiki/文件/Both.ogg)

上面的音频片段演示了在经历第3级听觉扭曲时听讲座可能听起来是什么样子的喵。

[Distorted_Forest.ogg](/FreeODwiki/文件/Distorted_Forest.ogg)

这个音频片段表示森林环境中的第3级音频失真哦。

<!-- 请勿删除或修改，这是一个标记，待识别并填坑（药效索引） -->

### 体验报告

在我们的[体验索引](/FreeODwiki/文档/体验索引.html)中，描述这种效应的轶事报告包括：

*   [Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us](/FreeODwiki/报告/psychounautwiki/Experience:_36mg_4-AcO-DiPT_-_Truly,_one_for_the_psychedelic_animals_among_us)
*   [Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis](/FreeODwiki/报告/psychounautwiki/Experience:_5-EAPB_(60mg)_%2B_2-FMA_(20mg)_%2B_4-AcO-DMT_(10mg)_-_Emotional_catharsis)
*   [Experience:1000 Morning Glory seeds - Rediscovering the Self](/FreeODwiki/报告/psychounautwiki/Experience:1000_Morning_Glory_seeds_-_Rediscovering_the_Self)
*   [Experience:100ug 1P-LSD - A Fear and loathing into Bliss](/FreeODwiki/报告/psychounautwiki/Experience:100ug_1P-LSD_-_A_Fear_and_loathing_into_Bliss)
*   [Experience:225mg Pregabalin +Cannabis -Bliss and Serenity; a hedonistic evening](/FreeODwiki/报告/psychounautwiki/Experience:225mg_Pregabalin_%2BCannabis_-Bliss_and_Serenity;_a_hedonistic_evening)
*   [Experience:250mg MDA / 250mg MDMA - unnecessarily large dosage](/FreeODwiki/报告/psychounautwiki/Experience:250mg_MDA_/_250mg_MDMA_-_unnecessarily_large_dosage)
*   [Experience:300µg ETH-LAD - Turned Inside Out](/FreeODwiki/报告/psychounautwiki/Experience:300%C2%B5g_ETH-LAD_-_Turned_Inside_Out)
*   [Experience:300µg LSD - Togetherness and the Silent Dusk](/FreeODwiki/报告/psychounautwiki/Experience:300%C2%B5g_LSD_-_Togetherness_and_the_Silent_Dusk)
*   [Experience:3g mimosa / 2g syrian rue - I was the Universe's prophet](/FreeODwiki/报告/psychounautwiki/Experience:3g_mimosa_/_2g_syrian_rue_-_I_was_the_Universe%27s_prophet)
*   [Experience:40mg - Brothermind and the Forest's Hand](/FreeODwiki/报告/psychounautwiki/Experience:40mg_-_Brothermind_and_the_Forest%27s_Hand)
*   [Experience:4x 200ug tabs - You do not need to understand](/FreeODwiki/报告/psychounautwiki/Experience:4x_200ug_tabs_-_You_do_not_need_to_understand)
*   [Experience:5.3g psilocybe cubensis - Dimensional Circumstance and the Fabric of Understanding](/FreeODwiki/报告/psychounautwiki/Experience:5.3g_psilocybe_cubensis_-_Dimensional_Circumstance_and_the_Fabric_of_Understanding)
*   [Experience:5g Mushrooms - Failed attempt at a Terence Mckenna style trip.](/FreeODwiki/报告/psychounautwiki/Experience:5g_Mushrooms_-_Failed_attempt_at_a_Terence_Mckenna_style_trip.)
*   [Experience:6g mimosa / 2.5 g syrian rue - Best cake I've had for a while](/FreeODwiki/报告/psychounautwiki/Experience:6g_mimosa_/_2.5_g_syrian_rue_-_Best_cake_I%27ve_had_for_a_while)
*   [Experience:LSD (400ug, Oral) - An afternoon in "a" garden](/FreeODwiki/报告/psychounautwiki/Experience:LSD_(400ug,_Oral)_-_An_afternoon_in_%22a%22_garden)
*   [Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)](/FreeODwiki/报告/psychounautwiki/Experience:Mushrooms_and_Snuff_Films_--_Trip_Report_(3.5_grams))
*   [Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death](/FreeODwiki/报告/psychounautwiki/Experience:Unknown_Dose_DOC_(Insufflated)_-_Overdosing_and_Terifying_Ego_Death)
*   [Experience:~150mg MDA(oral) - a case of mistaken identity](/FreeODwiki/报告/psychounautwiki/Experience:~150mg_MDA(oral)_-_a_case_of_mistaken_identity)

### 另见

*   [负责任的用药索引页](/FreeODwiki/文档/负责任的用药索引页.html)
*   [主观效应索引](/FreeODwiki/药效/home.html)
*   [迷幻剂 - 主观效应](/FreeODwiki/文档/药物分类/迷幻剂.html#主观效应)
*   [解离剂 - 主观效应](/FreeODwiki/文档/药物分类/解离剂.html#主观效应)
*   [谵妄剂 - 主观效应](/FreeODwiki/文档/药物分类/谵妄剂.html#主观效应)

### 参考文献

1.  ↑ [1.0](#cite_ref-Carbonaro2013_1-0) [1.1](#cite_ref-Carbonaro2013_1-1) Carbonaro, T. M., Forster, M. J., Gatch, M. B. (March 2013). ["Discriminative stimulus effects of N,N-diisopropyltryptamine"](http://link.springer.com/10.1007/s00213-012-2891-x). *Psychopharmacology*. **226** (2): 241–246. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/s00213-012-2891-x](/FreeODwiki//doi.org/10.1007%2Fs00213-012-2891-x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 0033-3158.
2.  ↑ [2.0](#cite_ref-Juszczak2013_2-0) [2.1](#cite_ref-Juszczak2013_2-1) [2.2](#cite_ref-Juszczak2013_2-2) Juszczak, G. R., Swiergiel, A. H. (1 January 2013). ["Recreational Use of D-Lysergamide from the Seeds of Argyreia Nervosa , Ipomoea Tricolor, Ipomoea Violacea, and Ipomoea Purpurea in Poland"](https://www.tandfonline.com/doi/full/10.1080/02791072.2013.763570). *Journal of Psychoactive Drugs*. **45** (1): 79–93. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1080/02791072.2013.763570](/FreeODwiki//doi.org/10.1080%2F02791072.2013.763570). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 0279-1072.
3.  [↑](#cite_ref-3) Mehta, U. M., Naveen Kumar, C., Venkatasubramanian, G., Thirthalli, J. (January 2017). ["Multimodal Sensory Distortions in Postpartum Exacerbation of Schizophrenia"](http://clinicalschizophrenia.org/doi/10.3371/CSRP.MEKU.112013). *Clinical Schizophrenia & Related Psychoses*. **10** (4): 222–224. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.3371/CSRP.MEKU.112013](/FreeODwiki//doi.org/10.3371%2FCSRP.MEKU.112013). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 1935-1232.
4.  ↑ [4.0](#cite_ref-Weinel2016_4-0) [4.1](#cite_ref-Weinel2016_4-1) [4.2](#cite_ref-Weinel2016_4-2) [4.3](#cite_ref-Weinel2016_4-3) [4.4](#cite_ref-Weinel2016_4-4) [4.5](#cite_ref-Weinel2016_4-5) [4.6](#cite_ref-Weinel2016_4-6) Weinel, J. (3 March 2016). ["Entoptic Phenomena in Audio : Categories of Psychedelic Electroacoustic Composition"](https://www.tandfonline.com/doi/full/10.1080/07494467.2016.1221633). *Contemporary Music Review*. **35** (2): 202–223. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1080/07494467.2016.1221633](/FreeODwiki//doi.org/10.1080%2F07494467.2016.1221633). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 0749-4467.
5.  ↑ [5.0](#cite_ref-Strassman2000_5-0) [5.1](#cite_ref-Strassman2000_5-1) [5.2](#cite_ref-Strassman2000_5-2) [5.3](#cite_ref-Strassman2000_5-3) Strassman, R. (2001). *DMT: the spirit molecule: a doctor’s revolutionary research into the biology of near-death and mystical experiences*. Park Street Press. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number) [9780892819270](http://en.wikipedia.org/wiki/Special:BookSources/9780892819270).
6.  ↑ [6.0](#cite_ref-Stanciu2016_6-0) [6.1](#cite_ref-Stanciu2016_6-1) [6.2](#cite_ref-Stanciu2016_6-2) [6.3](#cite_ref-Stanciu2016_6-3) N. Stanciu, C., M. Penders, T. (1 June 2016). "Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case". *Current Psychiatry Reviews*. **12** (2): 221–223.
7.  ↑ [7.0](#cite_ref-Espiard2005_7-0) [7.1](#cite_ref-Espiard2005_7-1) Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., Dollfus, S. (August 2005). ["Hallucinogen persisting perception disorder after psilocybin consumption: a case study"](https://www.cambridge.org/core/product/identifier/S092493380024145X/type/journal_article). *European Psychiatry*. **20** (5–6): 458–460. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.eurpsy.2005.04.008](/FreeODwiki//doi.org/10.1016%2Fj.eurpsy.2005.04.008). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 0924-9338.
8.  ↑ [8.0](#cite_ref-Shulgin1997_8-0) [8.1](#cite_ref-Shulgin1997_8-1) Shulgin, A., Shulgin, A. (1997). *TIHKAL: The Continuation*. Transform Press.
9.  [↑](#cite_ref-9) Strassman, R. J., Qualls, C. R., Berg, L. M. (May 1996). ["Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans"](https://linkinghub.elsevier.com/retrieve/pii/0006322395002006). *Biological Psychiatry*. **39** (9): 784–795. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0006-3223(95)00200-6](/FreeODwiki//doi.org/10.1016%2F0006-3223%2895%2900200-6). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 0006-3223.
10. [↑](#cite_ref-10) Meatherall, R., Sharma, P. (1 July 2003). ["Foxy, a Designer Tryptamine Hallucinogen*"](http://academic.oup.com/jat/article/27/5/313/752418/Foxy-a-Designer-Tryptamine-Hallucinogen). *Journal of Analytical Toxicology*. **27** (5): 313–317. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1093/jat/27.5.313](/FreeODwiki//doi.org/10.1093%2Fjat%2F27.5.313). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 1945-2403.
11. [↑](#cite_ref-11) Mowry, M., Mosher, M., Briner, W. (September 2003). ["Acute Physiologic and Chronic Histologic Changes in Rats and Mice Exposed to the Unique Hallucinogen Salvinorin A"](http://www.tandfonline.com/doi/abs/10.1080/02791072.2003.10400021). *Journal of Psychoactive Drugs*. **35** (3): 379–382. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1080/02791072.2003.10400021](/FreeODwiki//doi.org/10.1080%2F02791072.2003.10400021). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 0279-1072.
12. [↑](#cite_ref-12) Leake, C. D. (21 February 1972). ["Hallucinogenic Drug Reaction—MDA"](http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.1972.03190340073029). *JAMA: The Journal of the American Medical Association*. **219** (8): 1069. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1001/jama.1972.03190340073029](/FreeODwiki//doi.org/10.1001%2Fjama.1972.03190340073029). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 0098-7484.
13. [↑](#cite_ref-13) Hillhouse, T. M., Porter, J. H., Negus, S. S. (1 May 2014). ["Reply to: Rapid antidepressant effects and abuse liability of ketamine"](https://doi.org/10.1007/s00213-014-3544-z). *Psychopharmacology*. **231** (9): 2043–2044. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/s00213-014-3544-z](/FreeODwiki//doi.org/10.1007%2Fs00213-014-3544-z). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 1432-2072.
14. [↑](#cite_ref-14) Oye, I., Paulsen, O., Maurset, A. (March 1992). "Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors". *The Journal of Pharmacology and Experimental Therapeutics*. **260** (3): 1209–1213. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) 0022-3565.
